Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis.
D000328:Adult; D016022:Case-Control Studies; D003876:Dermatitis, Atopic / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D003990:Dibenzoxepins / Q000494:pharmacology / Q000627:therapeutic use*; D004817:Epidermis / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D020932:Nerve Growth Factor / Q000378:metabolism*; D000069605:Olopatadine Hydrochloride; D011537:Pruritus / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D011565:Psoriasis / Q000378:metabolism* / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome
D003990:Dibenzoxepins; D039563:Histamine H1 Antagonists, Non-Sedating; D000069605:Olopatadine Hydrochloride; D007073:Immunoglobulin E; D020932:Nerve Growth Factor; D007770:L-Lactate Dehydrogenase